San Diego, United States
Abintus Bio, Inc., founded in 2020, is a biotechnology company based in the United States. The company's slogan "Empowering patients from within" underscores its pioneering work in developing potentially curative, off-the-shelf genetic medicines that engineer cells directly inside the patient’s body, also termed in vivo. Abintus is focused on leveraging its clinically proven Modular Delivery Platform (MDP) for its two initial in vivo programs. These programs include highly selective gene expression targeting cell type/state via synthetic biology and simultaneous engineering of a diverse repertoire of active innate and adaptive immune cells.
The company is backed by an impressive initial funding syndicate, including Takeda Ventures and The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP). Notably, Abintus has received a $13.65M Venture Round investment as of 15 August 2022. Abintus' founding vision, reflected in its name derived from the Latin words “ab intus” (meaning "from within"), underscores its commitment to empowering patients' immune cells to fight diseases from within, scientific excellence, and a performance-driven culture that prioritizes career development and rewards outstanding contributions.
With over 20 years and $275 million of prior technology advancement for in vivo engineering, including the treatment of over 350 patients through Phase 3 registration trials, Abintus Bio, Inc. is positioned as a significant player in the biotechnology and healthcare industries.
For more information, visit www.abintusbio.com.
